Aradigm Corp. (ARDM) Receives NIH Grant to Study Pulmaquin, Lipoquin as Treatment of Pulmonary Non-Tuberculosis Mycobacterial Infections
Aradigm, a specialty pharmaceutical company focused on developing and commercializing a portfolio of drugs for the treatment of severe respiratory diseases, has been awarded a Small Business Initiative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The $278,000 grant was awarded to assist Aradigm in the investigation of the treatment of pulmonary non-tuberculous mycobacteria (PNTM) infections with the company’s inhaled liposomal ciprofloxacin products, Pulmaquin® and Lipoquin®. The principal investigator is Dr. James D. Blanchard, principal scientist of Preclinical Development at Aradigm. Dr. Luiz Bermudez at the Oregon State University, Corvallis,…